Form 4: Vor Biopharma Director Fouad Namouni Receives Stock Options

Director Fouad Namouni was granted 56,549 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Summary

• Fouad Namouni, a Director at Vor Biopharma Inc., was granted 56,549 stock options on June 11, 2026.
• The options have an exercise price of $14.09 per share.
• The options vest in 36 equal monthly installments beginning July 11, 2026, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company fundamentals.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Vor Biopharma common stock.

Future Outlook

The options vest over a three-year period, incentivizing the director's continued service and long-term commitment to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to attract and retain experienced leadership.

Comparison to Industry Standards

• The vesting schedule of 36 months is consistent with standard industry practices for director equity compensation.
• The use of stock options as a primary incentive tool aligns with typical compensation structures for clinical-stage biopharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, Director Compensation, Stock Options, Insider Transaction, Equity Grant